Research Article


DOI :10.26650/JARHS2020-739221   IUP :10.26650/JARHS2020-739221    Full Text (PDF)

MIR223 Gene Silencing via Locked Nucelic Acids in Cell Lines

Orçun TaşarMüge SayitoğluÖzden Hatırnaz Ng

Objective: Noncoding small RNAs play roles in physiological processes such as cell differentiation, growth, development, immune reactions, stress adaptation as well as complex diseases such as cancer and heart diseases. MIR223 is a specific miRNA to the hematopoietic system. Among the miRNAs associated with the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL), MIR223 was shown to have the highest expression level and functions as an oncomir. In this study we aimed to suppress MIR223 gene expression by using locked nucleic acid (LNA) in T-ALL cell lines as an alternative gene silencing technique and to show the silencing efficacy. Material and Methods: T-ALL cell lines (Jurkat and Molt4) were cultured and MIR223 specific LNA was applied in 100pmol and 150pmol concentrations for 24 hours and 48 hours. RNA was isolated from cells at both time points, followed by a stem loop polymerase chain reaction (PCR) for cDNA synthesis and the miRNA expression levels were evaluated by quantitative real time PCR. Results: In both cell lines a 150pmol application of LNA was compared to mock cells and the MIR223 expression was already suppressed at 24hours (73% in Jurkat (p=0,001) and 80%in Molt4 (p=0,04)). The suppression was continued at 48 hours in Molt4 cell line (p=0,005) where as there was no statistical significant difference in Jurkat at 48 hours. Conclusion: MIR223 has been identified as an oncomir and silencing the MIR223 with synthetic antisense oligos provide the opportunity to investigate the course and alternative therapy options of cancers with increased MIR223 expression, such as T-ALL. In this study LNA was used as an alternative RNA interference application in T-ALL cells and showed that LNA can effectively suppress gene expression when used in the short term.

DOI :10.26650/JARHS2020-739221   IUP :10.26650/JARHS2020-739221    Full Text (PDF)

Hücre Serilerinde Kilitli Nükleik Asitler İle MIR223 Gen Sessizleştirmesi

Orçun TaşarMüge SayitoğluÖzden Hatırnaz Ng

Amaç: Kodlama yapmayan küçük RNA’lar hücre farklılaşması, büyümesi, gelişmesi, immün reaksiyonlar, stres adaptasyonu gibi fizyolojik süreçlerin yanı sıra, kanser, kalp hastalıkları gibi kompleks hastalıklarla da ilişkilendirilmiştir. MIR223, hematopoetik sisteme özgü bir miRNA’dır. T-hücreli Akut Lenfoblastik Lösemi (T-ALL) patogenezine katkıda bulunan miRNA’lar arasında yüksek anlatıma sahip olduğu ve onkomir olarak aktivite gösterdiği tespit edilmiştir. Bu çalışmada MIR223 geninin T-ALL hücre serilerinde alternatif bir yaklaşım olarak özgün kilitli nükleik asit (KNA) kullanılarak baskılanması ve gen sessizleştirme etkinliğinin gösterilmesi amaçlanmıştır. Gereç ve Yöntem: Kültüre edilen T-ALL hücre serilerine (Jurkat ve Molt4), 24 ve 48 saatlik sürelerde, 100 ve 150pmol konsantrasyonda MIR223’e özgü KNA uygulanmıştır. Her iki zaman aralığında RNA izolasyonu sonrası, stem loop polimeraz zincir reaksiyonu (PZR) ile cDNA sentezlenerek, kantitatif gerçek zamanlı PZR (QRT-PZR) ile miRNA anlatım düzeyleri belirlenmiştir. Bulgular: Her iki hücre serisinde de 24. saatte, 150pmol KNA, sadece transfeksiyon ajanı uygulanmış (Mock) hücrelerle karşılaştırıldığında MIR223 düzeyinin yüksek oranda baskılandığı gözlenmiştir (Jurkat %73, p=0,001 ve Molt4%80 p=0,04). Molt 4 hücre serisinde anlamlı düzeyde baskılanma 48. saatte devam etse de (p=0,005), Jurkat hücre serisinde 48. saatteki baskılama istatistiksel olarak anlamlı bulunmamıştır. Sonuç: MIR223 onkogenik etki gösteren bir miRNA olarak tanımlanmıştır ve antisens oligolar ile MIR223 geninin sessizleştirilmesi T-ALL gibi artmış MIR223 anlatımı gösteren kanserlerde hastalığın seyrini ve tedavi alternatiflerini araştırma imkanı sağlamaktadır. Bu çalışmada T-ALL hücrelerinde alternatif bir RNA interferans (sessizleştirme) uygulaması olarak KNA kullanılmıştır ve bu moleküllerin çok etkin ancak kısa süreli olarak kullanılabileceği görülmüştür. 


PDF View

References

  • 1. Lee RC, Feinbaum RL and Ambros V. The c. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54. google scholar
  • 2. Mochizuki K, Fine NA, Fujisawa T, Gorovsky MA. Analysis of a piwi-related gene implicates small RNAs in genome rearrangement in tetrahymena. Cell 2002;110:689-99. google scholar
  • 3. Peragine A, Yoshikawa M, Wu G, Albrecht HL, Poethig RS. SG3 and SGS2/SDE1/RDR6 are required for juvenile development and the production of trans acting siRNAs in Arabidopsis. Genes Dev 2004;18:2368-79. google scholar
  • 4. O’Donnell KA and Boeke JD. Mighty Piwis defend the germline against genome intruders. Cell 2007;129:37-44. google scholar
  • 5. Vishnoi A, Rani S. MiRNA Biogenesis and Regulation of Diseases: An Overview. Methods Mol Biol 2017;1509:1-10. google scholar
  • 6. Sun W, Shen W, Yang S, Hu F, Li H, Zhu TH. MIR223 and miR-142 attenuate hematopoietic cell proliferation, and MIR223 positively regulates miR-142 through LMO2 isoforms and CEBP-β. Cell Res 2010;20(10):1158–69. google scholar
  • 7. Fulci V, Scappucci G, Sebastiani GD, Giannitti C, Franceschini D, Meloni F. et. al. MIR223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol 2010;71(2):206-11. google scholar
  • 8. Han L, Rachel B, Stuart C. MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res 2010;86(3):410-20. google scholar
  • 9. Haneklaus M, Gerlic M, O’Neill LAJ, Masters SL. MIR223: infection, inflammation and cancer. J Intern Med 2013;274(3);215-26. google scholar
  • 10. Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD, Brand M et.al. The TAL1 complex targets the FBXW7 tumor suppressor by activating MIR223 in human T cell acute lymphoblastic leukemia. J Exp Med 2013;210(8):1545-57. google scholar
  • 11. Yimei C, Xiaomin Y, Songnian H, Jun Yu. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics 2009;7(4):147-54. google scholar
  • 12. Mardani R, Abadi MHJN, Taghizadeh-Boroujeni S, Bayat A, Farsinezhad A, Hayat SMG. et. al. MicroRNA in Leukemia: Tumor Suppressors and Oncogenes with Prognostic Potential. J Cell Physiol 2018;234(6):8465-86. google scholar
  • 13. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E. et.al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99(24):15524-29. google scholar
  • 14. Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K. et.al. Downregulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009;4(5):e5532. google scholar
  • 15. Ohyashiki JH, Umezu T, Kobayashi C, Hamamura RS, Tanaka M, Kuroda M. Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes 2010;3:347. google scholar
  • 16. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST et. al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009;10(2):125-34. google scholar
  • 17. Schotte D, Akbari-Moqadam F, Lange-Turenhout EA, Chen C, Pieters R, Den Boer ML. Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia. Leukemia 2011;25(9):1389-99. google scholar
  • 18. Bellon M, Yves L, Hermine O. and Nicot C. Deregulation of micorRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood 2009;113(20):4914-17. google scholar
  • 19. Chen C, Li L, Lodish HF. MicroRNAs modulate hematopoietic lineage differentation. Science 2004;303(5654):83-6. google scholar
  • 20. Stenvang J, Silahtaroglu AN, Lindow M, Elmen J, Kauppinen S. The utility of KNA in microRNA based cancer diagnostics and therapeutics. Semin Cancer Biol 2008;18(2):89-102. google scholar
  • 21. Grünweller A, Hartmann RK. Locked nucleic acid oligonucleotides: the next generation of antisense agents? BioDrugs 2007;21(4):235-43. google scholar
  • 22. Nedaeinia R, Avan A, Ahmadian M, Nia SN, Ranjbar M, Sharifi M. et al. Piroozmand A, Nourmohammadi E, Manian M, Ferns GA, Ghayour-Mobarhan M, Salehi R. Current Status and Perspectives Regarding KNA-AntimiR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer. J Cell Biochem 2017;118(12):4129-40. google scholar
  • 23. Landgraf, P., M. Rusu, R. Sheridan, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007;129(7):1401-14. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Taşar, O., Sayitoğlu, M., & Hatırnaz Ng, Ö. (2020). MIR223 Gene Silencing via Locked Nucelic Acids in Cell Lines. Journal of Advanced Research in Health Sciences, 3(2), 45-50. https://doi.org/10.26650/JARHS2020-739221


AMA

Taşar O, Sayitoğlu M, Hatırnaz Ng Ö. MIR223 Gene Silencing via Locked Nucelic Acids in Cell Lines. Journal of Advanced Research in Health Sciences. 2020;3(2):45-50. https://doi.org/10.26650/JARHS2020-739221


ABNT

Taşar, O.; Sayitoğlu, M.; Hatırnaz Ng, Ö. MIR223 Gene Silencing via Locked Nucelic Acids in Cell Lines. Journal of Advanced Research in Health Sciences, [Publisher Location], v. 3, n. 2, p. 45-50, 2020.


Chicago: Author-Date Style

Taşar, Orçun, and Müge Sayitoğlu and Özden Hatırnaz Ng. 2020. “MIR223 Gene Silencing via Locked Nucelic Acids in Cell Lines.” Journal of Advanced Research in Health Sciences 3, no. 2: 45-50. https://doi.org/10.26650/JARHS2020-739221


Chicago: Humanities Style

Taşar, Orçun, and Müge Sayitoğlu and Özden Hatırnaz Ng. MIR223 Gene Silencing via Locked Nucelic Acids in Cell Lines.” Journal of Advanced Research in Health Sciences 3, no. 2 (Nov. 2024): 45-50. https://doi.org/10.26650/JARHS2020-739221


Harvard: Australian Style

Taşar, O & Sayitoğlu, M & Hatırnaz Ng, Ö 2020, 'MIR223 Gene Silencing via Locked Nucelic Acids in Cell Lines', Journal of Advanced Research in Health Sciences, vol. 3, no. 2, pp. 45-50, viewed 15 Nov. 2024, https://doi.org/10.26650/JARHS2020-739221


Harvard: Author-Date Style

Taşar, O. and Sayitoğlu, M. and Hatırnaz Ng, Ö. (2020) ‘MIR223 Gene Silencing via Locked Nucelic Acids in Cell Lines’, Journal of Advanced Research in Health Sciences, 3(2), pp. 45-50. https://doi.org/10.26650/JARHS2020-739221 (15 Nov. 2024).


MLA

Taşar, Orçun, and Müge Sayitoğlu and Özden Hatırnaz Ng. MIR223 Gene Silencing via Locked Nucelic Acids in Cell Lines.” Journal of Advanced Research in Health Sciences, vol. 3, no. 2, 2020, pp. 45-50. [Database Container], https://doi.org/10.26650/JARHS2020-739221


Vancouver

Taşar O, Sayitoğlu M, Hatırnaz Ng Ö. MIR223 Gene Silencing via Locked Nucelic Acids in Cell Lines. Journal of Advanced Research in Health Sciences [Internet]. 15 Nov. 2024 [cited 15 Nov. 2024];3(2):45-50. Available from: https://doi.org/10.26650/JARHS2020-739221 doi: 10.26650/JARHS2020-739221


ISNAD

Taşar, Orçun - Sayitoğlu, Müge - Hatırnaz Ng, Özden. MIR223 Gene Silencing via Locked Nucelic Acids in Cell Lines”. Journal of Advanced Research in Health Sciences 3/2 (Nov. 2024): 45-50. https://doi.org/10.26650/JARHS2020-739221



TIMELINE


Submitted18.02.2020
Accepted23.06.2020
Published Online10.07.2020

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.